[1] KAHLENBERG J M, KANG I.Advances in disease mechanisms and translational technologies:clinicopathologic significance of inflammasome activation in autoimmune diseases[J].Arthritis Rheumatol, 2020, 72(3):386-395.
[2] DHITAL R, PANDEY R K, POUDEL D R, et al.All-cause hospitalizations and mortality in systemic lupus erythematosus in the US:results from a national inpatient database[J].Rheumatol Int, 2020, 40(3):393-397.
[3] FLOSSMANN O, BERDEN A, DE GROOT K, et al.Long-term patient survival in ANCA-associated vasculitis[J].Ann Rheum Dis, 2011, 70(3):488-494.
[4] SINGH J A.Infections with biologics in rheumatoid arthritis and related conditions:a scoping review of serious or hospitalized infections in observational studies[J].Curr Rheumatol Rep, 2016, 18(10):61.
[5] LORTHOLARY O, FERNANDEZ-RUIZ M, BADDLEY J W, et al.Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies:a viewpoint in 2020[J].Ann Rheum Dis, 2020, 79(12):1532-1543.
[6] GALLOWAY J B, HYRICH K L, MERCER L K, et al.Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment:updated results from the British society for rheumatology biologics register with special emphasis on risks in the elderly[J].Rheumatology(Oxford), 2011, 50(1):124-131.
[7] CHEN S K, LIAO K P, LIU J, et al.Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis:a propensity score-matched cohort study[J].Arthritis Care Res(Hoboken), 2020, 72(1):9-17.
[8] GRØN K L, GLINTBORG B, NØRGAARD M, et al.Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study[J].Rheumatology(Oxford), 2020, 59(8):1949-1956.
[9] PADOVAN M, FILIPPINI M, TINCANI A, et al.Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis B virus infection[J].Arthritis Care Res(Hoboken), 2016, 68(6):738-743.
[10] ATZENI F, NUCERA V, GERRATANA E, et al.Concerns about the safety of anti-TNF agents when treating rheumatic diseases[J].Expert Opin Drug Saf, 2020, 19(6):695-705.
[11] CARRARA G, BORTOLUZZI A, SAKELLARIOU G, et al.Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics.analysis from the record linkage on rheumatic disease study of the Italian society for rheumatology[J].Clin Exp Rheumatol, 2019, 37(1):60-66.
[12] AI J W, ZHANG S, RUAN Q L, et al.The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist:a meta analysis of both randomized controlled trials and registry/cohort studies[J].J Rheumatol, 2015, 42(12):2229-2237.
[13] GRØN K L, ARKEMA E V, GLINTBORG B, et al.Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden[J].Ann Rheum Dis, 2019, 78(3):320-327.
[14] WESTHOVENS R, KREMER J M, EMERY P, et al.Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate:a 7-year extended study[J].Clin Exp Rheumatol, 2014, 32(4):553-562.
[15] HOU C, JIN O, ZHANG X.Clinical characteristics and risk factors of infections in patients with systemic lupus erythematosus[J].Clin Rheumatol, 2018, 37(10):2699-2705.
[16] 中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组.2020中国系统性红斑狼疮诊疗指南[J].中华内科杂志, 2020, 59(3):172-185.
[17] TRENTIN F, GATTO M, ZEN M, et al.Effectiveness, tolerability, and safety of belimumab in patients with refractory SLE:a review of observational clinical-practice-based studies[J].Clin Rev Allergy Immunol, 2018, 54(2):331-343.
[18] ZHANG F, BAE S C, BASS D, et al.A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea[J].Ann Rheum Dis, 2018, 77(3):355-363.
[19] ZHANG F, ZHENG J, LI Y, et al.Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years[J].RMD Open, 2022, 8(1):322-330.
[20] WALLACE D J, GINZLER E M, MERRILL J T, et al.Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus[J].Arthritis Rheumatol, 2019, 71(7):1125-1134.
[21] XIE J, FAN X, SU Y, et al.Pharmacokinetic characteristics, safety, and tolerability of telitacicept, an injectable recombinant human B-lymphocyte stimulating factor receptor-antibody fusion protein, in healthy Chinese subjects[J].Clin Pharmacol Drug Dev, 2022, 11(11):1273-1283.
[22] SUN L, SHEN Q, GONG Y, et al.Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus:a self-controlled before-after trial[J].Lupus, 2022, 31(8):998-1006.
[23] MORAND E F, FURIE R, TANAKA Y, et al.Trial of anifrolumab in active systemic lupus erythematosus[J].N Engl J Med, 2020, 382(3):211-221.
[24] LONCHARICH M F, ANDERSON C W.Interferon inhibition for lupus with anifrolumab:critical appraisal of the evidence leading to FDA approval[J].ACR Open Rheumatol, 2022, 4(6):486-491.
[25] FURIE R, KHAMASHTA M, MERRILL J T, et al.Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus[J].Arthritis Rheumatol, 2017, 69(2):376-386.
[26] AHMED A A, OSMAN N, FURIE R.An evaluation of anifrolumab for use in adults with systemic lupus erythematosus[J].Expert Rev Clin Immunol, 2022, 18(11):1095-1106.
[27] MERRILL J T, NEUWELT C M, WALLACE D J, et al.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus:the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial[J].Arthritis Rheum, 2010, 62(1):222-233.
[28] ROVIN B H, FURIE R, LATINIS K, et al.Efficacy and safety of rituximab in patients with active proliferative lupus nephritis:the lupus nephritis assessment with rituximab study[J].Arthritis Rheum, 2012, 64(4):1215-1226.
[29] FANOURIAKIS A, KOSTOPOULOU M, ALUNNO A, et al.2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J].Ann Rheum Dis, 2019, 78(6):736-745.
[30] ALSHAIKI F, OBAID E, ALMUALLIM A, et al.Outcomes of rituximab therapy in refractory lupus:a meta-analysis[J].Eur J Rheumatol, 2018, 5(2):118-126.
[31] CHUNG S A, LANGFORD C A, MAZ M, et al.2021 American college of rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis[J].Arthritis Rheumatol, 2021, 73(8):1366-1383.
[32] TREPPO E, BINUTTI M, AGARINIS R, et al.Rituximab induction and maintenance in ANCA-associated vasculitis:state of the art and future perspectives[J].J Clin Med, 2021, 10(17):3773.
[33] KRONBICHLER A, KERSCHBAUM J, GOPALUNI S, et al.Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis[J].Ann Rheum Dis, 2018, 77(10):1440-1447.
[34] MONTI S, DELVINO P, RIBOLI M, et al.The role of trimethoprim/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis:a meta-analysis[J].Rheumatology(Oxford), 2021, 60(8):3553-3564.
[35] ODDIS C V, REED A M, AGGARWAL R, et al.Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis:a randomized, placebo-phase trial[J].Arthritis Rheum, 2013, 65(2):314-324.
[36] MOK C C, HO L Y, TO C H.Rituximab for refractory polymyositis:an open-label prospective study[J].J Rheumatol, 2007, 34(9):1864-1868.
[37] CHUNG L, GENOVESE M C, FIORENTINO D F.A pilot trial of rituximab in the treatment of patients with dermatomyositis[J].Arch Dermatol, 2007, 143(6):763-767.
[38] IANNONE F, SCIOSCIA C, FALAPPONE P C, et al.Use of etanercept in the treatment of dermatomyositis:a case series[J].J Rheumatol, 2006, 33(9):1802-1804.
[39] SCHIFFENBAUER A, GARG M, CASTRO C, et al.A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis[J].Semin Arthritis Rheum, 2018, 47(6):858-864.
[40] ISHIKAWA Y, YUKAWA N, OHMURA K, et al.Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis:a case report and review of the literature[J].Clin Rheumatol, 2010, 29(5):563-566.
[41] KHANNA D, DENTON C P, JAHREIS A, et al.Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis(faSScinate):a phase 2, randomised, controlled trial[J].Lancet, 2016, 387(10038):2630-2640.
[42] KHANNA D, DENTON C P, LIN C J F, et al.Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis:results from the open-label period of a phase II randomised controlled trial(faSScinate)[J].Ann Rheum Dis, 2018, 77(2):212-220.
[43] ELHAI M, BOUBAYA M, DISTLER O, et al.Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice:a prospective cohort study[J].Ann Rheum Dis, 2019, 78(7):979-987. |
